Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 12.67
SNTA's Cash to Debt is ranked lower than
54% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SNTA: 12.67 )
Ranked among companies with meaningful Cash to Debt only.
SNTA' s Cash to Debt Range Over the Past 10 Years
Min: 2.27  Med: 10.32 Max: N/A
Current: 12.67
F-Score: 3
Z-Score: -12.10
M-Score: -4.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -120.99
SNTA's ROE (%) is ranked lower than
85% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SNTA: -120.99 )
Ranked among companies with meaningful ROE (%) only.
SNTA' s ROE (%) Range Over the Past 10 Years
Min: -1054.73  Med: -152.86 Max: -80.81
Current: -120.99
-1054.73
-80.81
ROA (%) -79.08
SNTA's ROA (%) is ranked lower than
82% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SNTA: -79.08 )
Ranked among companies with meaningful ROA (%) only.
SNTA' s ROA (%) Range Over the Past 10 Years
Min: -98.31  Med: -85.32 Max: 108.22
Current: -79.08
-98.31
108.22
ROC (Joel Greenblatt) (%) -8993.00
SNTA's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SNTA: -8993.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNTA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6515.41  Med: -1413.59 Max: 1600.97
Current: -8993
-6515.41
1600.97
Revenue Growth (3Y)(%) -100.00
SNTA's Revenue Growth (3Y)(%) is ranked lower than
97% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SNTA: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNTA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 164.5
Current: -100
0
164.5
EBITDA Growth (3Y)(%) -3.00
SNTA's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. SNTA: -3.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNTA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.9  Med: -3.70 Max: 180.5
Current: -3
-29.9
180.5
EPS Growth (3Y)(%) -4.50
SNTA's EPS Growth (3Y)(%) is ranked higher than
50% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SNTA: -4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNTA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.3  Med: 3.60 Max: 187.6
Current: -4.5
-37.3
187.6
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SNTA Guru Trades in Q1 2015

Paul Tudor Jones 200,000 sh (New)
Murray Stahl 16,000 sh (+45.45%)
Jim Simons 656,700 sh (+2.68%)
» More
Q2 2015

SNTA Guru Trades in Q2 2015

Murray Stahl 16,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2015

SNTA Guru Trades in Q3 2015

Murray Stahl 18,000 sh (+12.50%)
» More
Q4 2015

SNTA Guru Trades in Q4 2015

Jim Simons 2,504,200 sh (New)
Murray Stahl 18,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.42
SNTA's P/B is ranked higher than
99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. SNTA: 0.42 )
Ranked among companies with meaningful P/B only.
SNTA' s P/B Range Over the Past 10 Years
Min: 0.38  Med: 7.65 Max: 28.34
Current: 0.42
0.38
28.34
EV-to-EBIT 0.71
SNTA's EV-to-EBIT is ranked higher than
90% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. SNTA: 0.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.2  Med: -3.10 Max: 2.2
Current: 0.71
-12.2
2.2
EV-to-EBITDA 0.71
SNTA's EV-to-EBITDA is ranked higher than
91% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. SNTA: 0.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -3.20 Max: 2.2
Current: 0.71
-12.4
2.2
Current Ratio 2.95
SNTA's Current Ratio is ranked lower than
63% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SNTA: 2.95 )
Ranked among companies with meaningful Current Ratio only.
SNTA' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 3.50 Max: 7.01
Current: 2.95
0.43
7.01
Quick Ratio 2.95
SNTA's Quick Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SNTA: 2.95 )
Ranked among companies with meaningful Quick Ratio only.
SNTA' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 3.50 Max: 7.01
Current: 2.95
0.43
7.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.45
SNTA's Price/Net Cash is ranked higher than
100% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. SNTA: 0.45 )
Ranked among companies with meaningful Price/Net Cash only.
SNTA' s Price/Net Cash Range Over the Past 10 Years
Min: 3.46  Med: 7.85 Max: 80.9
Current: 0.45
3.46
80.9
Price/Net Current Asset Value 0.44
SNTA's Price/Net Current Asset Value is ranked higher than
99% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SNTA: 0.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNTA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.38  Med: 7.59 Max: 50.56
Current: 0.44
3.38
50.56
Price/Tangible Book 0.43
SNTA's Price/Tangible Book is ranked higher than
99% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. SNTA: 0.43 )
Ranked among companies with meaningful Price/Tangible Book only.
SNTA' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.07  Med: 6.87 Max: 30.05
Current: 0.43
3.07
30.05
Earnings Yield (Greenblatt) (%) 140.91
SNTA's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SNTA: 140.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNTA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 45.1  Med: 125.05 Max: 38903.7
Current: 140.91
45.1
38903.7

More Statistics

Revenue(Mil) $7
EPS $ -0.65
Beta0.77
Short Percentage of Float6.17%
52-Week Range $0.15 - 3.17
Shares Outstanding(Mil)137.79

Analyst Estimate

Dec15 Dec16 Dec18
Revenue(Mil)
EPS($) -0.68 -0.72 -0.75
EPS without NRI($) -0.68 -0.72 -0.75

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany,
Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. It is a biopharmaceutical company engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, it is developing several candidates from its proprietary Hsp90 inhibitor Drug Conjugate program (HDC Program), which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver an array of anti-cancer payloads. It also has an additional clinical-stage oncology candidate: elesclomol, a mitochondrial metabolism inhibitor. Its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 867 patents and patent applications.
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Insiders Sell Twitter and Cannabis Science, Buy DSW and WhiteHorse Dec 04 2015 
Stocks Both Gurus and Company Insiders Are Buying Jun 18 2015 
Insider Buys: FULL, FMI and SNTA Apr 10 2015 
Weekly 3-Year Low Highlights: NSR, ELRC, PLPC, SNTA Feb 16 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Servic Jan 11 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
​Two local biotechs that are now valued lower than their bank accounts Feb 12 2016
This Company is Up +400% in a Month Jan 07 2016
4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume Dec 15 2015
Here is What Hedge Funds Think About United Community Financial Corp (UCFC) Dec 13 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Dec 09 2015
SYNTA PHARMACEUTICALS CORP Financials Dec 08 2015
Is Synta Pharmaceuticals Corp. (SNTA) A Good Stock To Buy? Nov 22 2015
Synta Q3 Loss Narrower than Expected, to Cut Jobs by 60% Nov 06 2015
Synta Reports Third Quarter 2015 Financial Results Nov 05 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Nov 05 2015
Synta Reports Third Quarter 2015 Financial Results Nov 05 2015
Synta (SNTA) Q3 Earnings Preview: What's in the Cards? Nov 03 2015
8 BioPharma Movers That Cannot Be Ignored Oct 24 2015
Synta Falls, Stops Ganetespib Late-Stage Lung Cancer Study Oct 23 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 22 2015
Synta shares plunge as company gives up on trial of lead drug in lung cancer Oct 21 2015
Ergomed Co-Development Partner News Oct 21 2015
Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer Oct 20 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK